October 10, 2025 04:00 ET | Source: NTG Nordic Transport Group A/S NTG Nordic Transport Group A/S – Q3 2025…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET / 4:30 pm ET –…
Almere, The Netherlands September 23, 2025, 7:45 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today hosts its 2025 Investor…
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September…
Q2 Interim report April – June 2025 for ZetaDisplay AB (publ) is now published at the ZetaDisplay Investor relations web:…
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies…
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…
Almere, The NetherlandsJuly 28, 2025, 5:45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today announces that its €150 million…
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…